Merck KGaA And Novartis Back In Horse Race For First Oral MS Drug To Market

FDA granted the reworked cladribine NDA submitted in June by U.S. affiliate EMD Serono a six-month priority review, with approval possible in the fourth quarter, while action is anticipated on Gilenia in September.